Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) – Research analysts at Leerink Swann increased their FY2016 earnings per share (EPS) estimates for Aurinia Pharmaceuticals in a report issued on Wednesday. Leerink Swann analyst J. Schwartz now anticipates that the brokerage will post earnings of $0.54 per share for the year, up from their prior forecast of ($0.55). Leerink Swann has a “Outperform” rating and a $7.00 price objective on the stock. Leerink Swann also issued estimates for Aurinia Pharmaceuticals’ Q4 2016 earnings at ($0.10) EPS, FY2017 earnings at ($0.45) EPS and FY2018 earnings at ($0.57) EPS.

Several other equities analysts have also recently weighed in on AUPH. Bloom Burton reiterated a “buy” rating on shares of Aurinia Pharmaceuticals in a research report on Friday, November 4th. Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, November 9th. FBR & Co reiterated an “outperform” rating and set a $9.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Friday, November 4th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Aurinia Pharmaceuticals in a research report on Tuesday, November 8th. Finally, Canaccord Genuity set a $10.00 price objective on shares of Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Aurinia Pharmaceuticals presently has an average rating of “Buy” and an average target price of $7.79.

Aurinia Pharmaceuticals (NASDAQ:AUPH) opened at 3.24 on Monday. The stock’s market capitalization is $128.72 million. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $2.91. Aurinia Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $5.69.

A number of large investors have recently modified their holdings of the company. Redmile Group LLC boosted its stake in shares of Aurinia Pharmaceuticals by 560.4% in the third quarter. Redmile Group LLC now owns 187,610 shares of the company’s stock worth $565,000 after buying an additional 159,200 shares in the last quarter. KCG Holdings Inc. acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth about $153,000. SG Americas Securities LLC acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth about $1,123,000. Creative Planning acquired a new stake in shares of Aurinia Pharmaceuticals during the third quarter worth about $181,000. Finally, Lombard Odier Asset Management USA Corp boosted its stake in shares of Aurinia Pharmaceuticals by 2.8% in the second quarter. Lombard Odier Asset Management USA Corp now owns 102,294 shares of the company’s stock worth $283,000 after buying an additional 2,813 shares in the last quarter. Hedge funds and other institutional investors own 19.06% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Aurinia Pharmaceuticals Inc. to Post FY2016 Earnings of $0.54 Per Share, Leerink Swann Forecasts (AUPH)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another publication, it was stolen and republished in violation of international copyright laws. The correct version of this news story can be read at https://www.thecerbatgem.com/2016/11/23/aurinia-pharmaceuticals-inc-to-post-fy2016-earnings-of-0-54-per-share-leerink-swann-forecasts-auph.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

5 Day Chart for NASDAQ:AUPH

Receive News & Stock Ratings for Aurinia Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.